Nature Medicine
11, 623 - 629 (2005)
Published online: 15 May 2005; | doi:10.1038/nm1249
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetRoberto Chiarle, William J Simmons, Honjying Cai, Girish Dhall, Alberto Zamo, Regina Raz, James G Karras, David E Levy
& Giorgio InghiramiSupplementary Fig. 1 (pdf 108K)
Stat3 is constitutively activated in mouse and human NPM-ALK positive cells. Supplementary Fig. 2 (pdf 42K)
Percentages of infection of Stat3
loxP/- and Stat3-/- cells using with wild-type NPM-ALK or K210RNPM-ALK retroviruses. Supplementary Fig. 3 (pdf 162K)
Human Stat3 ASO block cell proliferation and induce cell death of ALCL-positive cells in vitro. Supplementary Fig. 4 (pdf 77K)
Stat3 ASO inhibit tumor growth and increase overall survival of mice bearing Stat3 positive NPM-ALK T cell tumors. Supplementary Fig. 5 (pdf 187K)
Biological changes induced by subcutaneous subministration of ASO. Supplementary Fig. 6 (pdf 47K)
Stat3 ASO leads to the downmodulation of mRNA levels of Stat3 in xenograft tissue tumor samples. Supplementary Fig. 7 (pdf 227K)
Tumors treated with Stat3 ASO undergo cell death.
| 
